Eton Pharmaceuticals (ETON) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 159.5% versus a loss of 11.1%. Over five years, ETON leads with a +953.4% price change compared with +3.3% for STOK. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.55 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | STOK |
|---|---|---|
| Share price | $54.75 | $23.95 |
| Market cap | $1.56B | $1.55B |
| 1-day change | -0.24% | -1.40% |
| YTD return | +224.54% | -23.47% |
| 1-year return | +159.48% | -11.06% |
| 5-year return | +953.36% | +3.27% |
| P/E ratio (TTM) | 136.88 | — |
| Forward P/E | 21.22 | — |
| EPS (TTM) | $0.40 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $40.22 |
| 52-week low | $14.27 | $20.32 |
| Distance from 52-week high | -17.51% | -40.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +29.68% | +93.99% |
| Average volume | 606.07K | 852.03K |
| Shares outstanding | 28.58M | 64.53M |
| Employees | 44 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed STOK by 170.5 percentage points over the past year.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
ETON vs STOK FAQ
Which is bigger, Eton Pharmaceuticals or Stoke Therapeutics?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $1.55B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, ETON or STOK?
ETON returned +159.48% over the past 12 months, compared with -11.06% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.